$474 Million is the total value of Sarissa Capital Management LP's 17 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 43.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARIA | ARIAD PHARMACEUTICALS INC | $105,884,000 | +19.9% | 12,850,000 | 0.0% | 22.34% | -28.5% | |
| ABBV | New | ABBVIE INC. | $92,493,000 | – | 1,580,000 | +100.0% | 19.51% | – |
| DGX | QUEST DIAGNOSTICS INC | $59,559,000 | +14.6% | 775,000 | 0.0% | 12.56% | -31.7% | |
| AMGN | AMGEN INC | $50,832,000 | +0.4% | 318,000 | 0.0% | 10.72% | -40.2% | |
| AEGR | New | AEGERION PHARMACEUTICALS INC | $42,852,000 | – | 1,637,455 | +100.0% | 9.04% | – |
| MDCO | New | MEDICINES CO | $34,047,000 | – | 1,215,100 | +100.0% | 7.18% | – |
| MRK | MERCK & CO INC NEW | $22,992,000 | +1.2% | 400,000 | 0.0% | 4.85% | -39.7% | |
| FLML | New | FLAMEL TECHNOLOGIES SAsponsored adr | $15,733,000 | – | 875,000 | +100.0% | 3.32% | – |
| APRI | Buy | APRICUS BIOSCIENCES INC | $12,201,000 | +1084.6% | 6,524,505 | +533.4% | 2.57% | +605.2% |
| RPRX | REPROS THERAPEUTICS INC | $9,727,000 | -13.8% | 1,132,367 | 0.0% | 2.05% | -48.6% | |
| ITCI | INTRA CELLULAR THERAPIES INC | $8,597,000 | +35.3% | 360,000 | 0.0% | 1.81% | -19.4% | |
| VVUS | VIVUS INC | $6,332,000 | -14.6% | 2,573,943 | 0.0% | 1.34% | -49.1% | |
| KIN | KINDRED BIOSCIENCES INC | $4,920,000 | -4.2% | 689,091 | 0.0% | 1.04% | -42.9% | |
| AVEO | AVEO PHARMACEUTICALS INC | $3,728,000 | +72.6% | 2,570,759 | 0.0% | 0.79% | +2.7% | |
| ANIP | ANI PHARMACEUTICALS INC | $1,939,000 | +10.9% | 31,000 | 0.0% | 0.41% | -33.9% | |
| TRGT | TARGACEPT INC | $1,871,000 | +12.9% | 630,000 | 0.0% | 0.40% | -32.6% | |
| EBIO | ELEVEN BIOTHERAPEUTICS INC. | $368,000 | -24.7% | 41,200 | 0.0% | 0.08% | -54.9% | |
| CYCC | Exit | CYCLACEL PHARMACEUTICALS INC. | $0 | – | -376,000 | -100.0% | -0.09% | – |
| BRLI | Exit | BIO-REFERENCE LABS INC | $0 | – | -390,270 | -100.0% | -4.44% | – |
| A | Exit | AGILENT TECHNOLOGIES INC. | $0 | – | -460,000 | -100.0% | -6.66% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.